Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | PLAU | P00749 | 3/20 | 0.42 |
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923995 | 0.81 | KDM4E (0.74) | ALDH1A1SMN1; SMN2KDM4ERAB9AGAA | |
| SCHEMBL15900327 | 0.79 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KDM4ERAB9AMAPT | |
| SCHEMBL16460648 | 0.79 | KDM4E (0.62) | ALDH1A1SMN1; SMN2KDM4ERAB9AGAA | |
| SCHEMBL4311317 | 0.78 | MAPT (0.57) | ALDH1A1SMN1; SMN2RAB9AMAPTGAA | |
| SCHEMBL4475711 | 0.76 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4ERAB9AMAPT | |
| SCHEMBL4315960 | 0.76 | MAPT (0.49) | ALDH1A1SMN1; SMN2RAB9AMAPTGAA | |
| SCHEMBL9893328 | 0.76 | KDM4E (0.54) | ALDH1A1SMN1; SMN2KDM4ERAB9AHSD17B10 | |
| SCHEMBL4316016 | 0.76 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2KDM4ERAB9AMAPT | |
| SCHEMBL16461864 | 0.76 | KDM4E (0.51) | ALDH1A1SMN1; SMN2KDM4ERAB9AGAA | |
| SCHEMBL21001635 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4ERAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | ALDH1A1 920/4885SMN1; SMN2 2443/4885KDM4E 1794/4885 |
| US-20080200494-A1 | Imidazopyridine Derivatives | MC1R, MC3R, MC5R | ALDH1A1 1277/4885SMN1; SMN2 2050/4885KDM4E 1967/4885 |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | ALDH1A1 1755/4885SMN1; SMN2 2642/4885KDM4E 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.